## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (currently amended) A method for determining <u>if a human has the presence of</u> an acute <u>ischemic renal tubular cell injury that can progress to acute renal failure (ARF) in a mammal, including an ischemic renal injury and a nephrotoxic injury, comprising the steps of:</u>
- (a) providing a urine sample <u>obtained</u> from a <u>human within a period of time of about 12</u> hours after an event that can cause <u>mammalian subject that is suspected of having</u> an acute <u>ischemic</u> renal tubular cell injury, and that predisposes the human to progressing to ARF, the event selected from the group consisting of (a) a surgical procedure selected from the group consisting of open heart surgery, cardiac surgery, and vascular surgery, and (b) kidney transplantation;
- (b) contacting the urine sample with an antibody for neutrophil gelatinase-associated lipocalin (NGAL), to allow formation of a complex of the antibody and the NGAL;
  - (c) detecting the antibody-NGAL complex; and
- (d) correlating [[the]] <u>an elevated level of detected antibody-NGAL complex to the human having presence of the acute ischemic renal tubular cell injury that can progress to ARF.</u>
- 2. (previously presented) The method according to Claim 30 wherein the urine sample comprises a plurality of urine samples from the subject that are obtained intermittently or continuously.
- 3. (canceled)
- 4. (previously presented) The method according to Claim 31 wherein the step of detecting the antibody-NGAL complex comprises contacting the complex with a second antibody for detecting the NGAL.

S.N. 10/811,130 Amendment And Response Attorney Docket CHM-015

5. (previously presented) The method according to Claim 30 wherein the mammalian subject is a human.

## 6. - 8. (canceled)

- 9. (currently amended) The method according to Claim 31 wherein the antibody is a capture antibody for the NGAL and the antibody-NGAL complex is a capture antibody-NGAL complex.
- 10. (previously presented) The method according to Claim 9 wherein the step of detecting the antibody-NGAL complex comprises the steps of:
- (1) separating any unbound material of the urine sample from the capture antibody-NGAL complex;
- (2) contacting the capture antibody-NGAL complex with a second antibody for detecting the NGAL, to allow formation of a second complex between the second antibody and the capture antibody-NGAL complex;
  - (3) separating any unbound second antibody from the second antibody complex; and
  - (4) detecting the second antibody of the second antibody complex.
- 11. (previously presented) The method according to Claim 10 wherein the step (i) comprises the step of contacting the urine sample with a media having affixed thereto the capture antibody.

## 12. - 29. (cancelled)

- 30. (currently amended) A method for determining <u>if a mammalian subject has the presence of</u> an acute <u>ischemic renal tubular cell injury that can progress to acute renal failure (ARF) in a mammalian subject</u>, wherein the method comprises the steps of:
- (a) detecting the <u>quantity</u> presence of any neutrophil gelatinase-associated lipocalin (NGAL) in a urine sample obtained from a mammalian subject <u>within a period of time of about 12 hours after an event</u> that is suspected of <u>causing having</u> an acute <u>ischemic</u> renal tubular cell injury, and that predisposes the mammalian subject to progressing to ARF; and
- (b) correlating <u>an elevated quantity the presence</u> of NGAL in the urine sample to the <u>mammalian subject having presence</u> of the acute <u>ischemic</u> renal tubular cell injury <u>that can progress to ARF.</u>
- 31. (currently amended) The method according to claim 30, wherein the detecting of the quantity of NGAL is done by
- (i) contacting the urine sample with an antibody for NGAL to allow formation of a complex of the antibody with any NGAL present in the urine sample; and
  - (ii) detecting the antibody-NGAL complex as a measure of a [[the]] level of the NGAL.
- 32. (canceled)
- 33. (currently amended) The method according to claim 30, wherein the method is used to detect NGAL present in a obtained urine sample is [[of]] the first urine output of the subject immediately following the event acute renal tubular cell injury.
- 34. (canceled)
- 35. (currently amended) The method according to claim 30 wherein the urine sample is obtained within a period of time following the acute renal tubular cell injury, the period of time is selected from the group consisting of 6 hours, 4 hours, 3 hours, 2 hours, 1 hour, and 30 minutes.

S.N. 10/811,130 Amendment And Response Attorney Docket CHM-015

36. (canceled)

37. (currently amended) The method according to claim 30 [[36]] wherein the event is selected from the group consisting of: (a) a surgical procedure selected from the group consisting of open heart surgery, cardiac surgery, coronary bypass surgery, and vascular surgery; and (b) kidney transplantation; (c) administration of a nephrotoxic agent; (d) a cardiovascular event; and (e) a condition selected from the group consisting of stroke, trauma, sepsis, and dehydration.

38. - 47. (canceled)

48. (currently amended) The method according to claim 1 wherein the step of detecting the antibody-NGAL complex further comprises determining the level of the antibody-NGAL complex, and wherein the step of correlating comprises correlating the <u>elevated</u> level of the antibody-NGAL complex to the extent of the acute <u>ischemic</u> renal tubular cell injury that can progress to ARF.

49.-51. (canceled)

52. (previously presented) The method according to claim 30, wherein the urine sample is an unprocessed urine sample.

53. - 54. (canceled)

55. (currently amended) The method according to claim 31 wherein the level of NGAL correlates with the extent of the acute <u>ischemic</u> renal tubular cell injury.

56. - 59. (canceled)

60. (new) The method according to claim 1 wherein the elevated level of antibody-NGAL complex is at least a 10-fold increase in the level of antibody-NGAL complex.

S.N. 10/811,130 Amendment And Response Attorney Docket CHM-015

- 61. (new) The method according to claim 30 wherein the elevated quantity of NGAL is at least a 10-fold increase in the level of NGAL.
- 62. (new) The method according to claim 1, wherein the urine sample is an unprocessed urine sample.
- 63. (new) The method according to claim 35 wherein the period of time is selected from the group consisting of 3 hours, 2 hours, 1 hour, and 30 minutes.
- 64. (new) The method according to claim 1 wherein the period of time is selected from the group consisting of 3 hours, 2 hours, 1 hour, and 30 minutes.
- 65. (new) The method according to claim 30 wherein the elevated quantity of NGAL is significantly elevated above a smaller increased quantity of NGAL in a mammalian subject having an acute ischemic renal tubular cell injury that does not progress to ARF.